These results are in line with previous studies in lung, liver, esophageal and breast cancers showing that the percentage of PD-1+ CD8+ cells present in PB and at the tumor site may be considered as a prognostic marker for response to mAb immunotherapy [32,33,34,35]. This evidence concerns the gene CD8A and neoplasm.